Pepsinogen/Proton Pump Co-Expression in Barrett's Esophageal Cells Induces Cancer-Associated Changes.
Barrett's esophagus
Gastroesophageal reflux disease
RNA sequencing
differential gene expression
esophageal adenocarcinoma
gastric acid
pepsin
pepsinogen
proton pumps
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
27
02
2022
received:
05
01
2022
accepted:
04
03
2022
pubmed:
23
3
2022
medline:
15
12
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
At the conclusion of this presentation, participants should better understand the carcinogenic potential of pepsin and proton pump expression in Barrett's esophagus. Barrett's esophagus (BE) is a well-known risk factor for esophageal adenocarcinoma (EAC). Gastric H In vitro translational. BAR-T, a human BE cell line devoid of expression of pepsinogen or proton pumps, was transduced by lentivirus-encoding pepsinogen (PGA5) and/or gastric proton pump subunits (ATP4A, ATP4B). Changes relative to the parental line were assessed by RNA sequencing. Top canonical pathways associated with protein-coding genes differentially expressed in pepsinogen and/or proton pump expressing BAR-T cells included those involved in the tumor microenvironment and epithelial-mesenchymal transition. Top upstream regulators of coding transcripts included TGFB1 and ERBB2, which are associated with the pathogenesis and prognosis of BE and EAC. Top upstream regulators of noncoding transcripts included p300-CBP, I-BET-151, and CD93, which have previously described associations with EAC or carcinogenesis. The top associated disease of both coding and noncoding transcripts was cancer. These data support the carcinogenic potential of pepsin and proton pump expression in BE and reveal molecular pathways affected by their expression. Further study is warranted to investigate the role of these pathways in carcinogenesis associated with BE. NA Laryngoscope, 133:59-69, 2023.
Substances chimiques
Proton Pumps
0
Pepsinogen A
9001-10-9
Proton Pump Inhibitors
0
Pepsin A
EC 3.4.23.1
Adenosine Triphosphatases
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-69Informations de copyright
© 2022 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018;154:267-276.
Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 2018;67:430-440.
Bujanda DE, Hachem C. Barrett's esophagus. Mo Med 2018;115:211-213.
Naini BV, Souza RF, Odze RD. Barrett's esophagus: a comprehensive and contemporary review for pathologists. Am J Surg Pathol 2016;40:e45-e66.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB. American College of G. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016;111:30-50.
Samuels TL, Altman KW, Gould JC, et al. Esophageal pepsin and proton pump synthesis in Barrett's esophagus and esophageal adenocarcinoma. Laryngoscope 2019;129:2687-2695.
Samuels T, Hoekzema C, Gould J, et al. Local synthesis of pepsin in Barrett's esophagus and the role of pepsin in esophageal adenocarcinoma. Ann Otol Rhinol Laryngol 2015;124:893-902.
Samuels TL, Zimmermann MT, Zeighami A, et al. RNA sequencing reveals cancer-associated changes in laryngeal cells exposed to non-acid pepsin. Laryngoscope 2021;131:121-129.
Kukurba KR, Montgomery SB. RNA sequencing and analysis. Cold Spring Harb Protoc 2015;2015:951-969.
Jaiswal KR, Morales CP, Feagins LA, et al. Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). Dis Esophagus 2007;20:256-264.
McCormick CA, Samuels TL, Battle MA, et al. H+/K+ATPase expression in the larynx of laryngopharyngeal reflux and laryngeal cancer patients. Laryngoscope 2021;131:130-135.
Stabenau KA, Zimmermann MT, Mathison A, et al. RNA sequencing and pathways analyses of middle ear epithelia from patients with otitis media. Laryngoscope 2021;131:2590-2597.
Kalari KR, Nair AA, Bhavsar JD, et al. MAP-RSeq: mayo analysis pipeline for RNA sequencing. BMC Bioinform 2014;15:224.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-140.
Scott SJ, Li X, Jammula S, et al. Evidence that polyploidy in esophageal adenocarcinoma originates from mitotic slippage caused by defective chromosome attachments. Cell Death Differ 2021;28:2179-2193.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition [published correction appears in J Clin invest. 2010 May 3;120(5):1786]. J Clin Invest 2009;119:1420-1428. https://doi.org/10.1172/JCI39104.
Roche J. Erratum: Roche, J. The epithelial-to-mesenchymal transition in cancer. Cancers, 2018, 10, 52. Cancer 2018;10:79.
Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 2013;25:76-84.
Chu WM. Tumor necrosis factor. Cancer Lett 2013;328:222-225.
Menke V, van Zoest KP, Moons LM, et al. NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Scand J Gastroenterol 2012;47:378-386.
Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000;19:6102-6114.
Dahlberg PS, Jacobson BA, Dahal G, et al. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 2004;78:1790-1800.
Dahlberg PS, Ferrin LF, Grindle SM, Nelson CM, Hoang CD, Jacobson B. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg 2004;77:1008-1015.
Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18:546-554.
Plum PS, Gebauer F, Krämer M, et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer 2019;19:38.
Liu X, Wang L, Zhao K, et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008;451:846-850.
Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-4231.
Jin K, Zhou W, Han X, et al. Acetylation of mastermind-like 1 by p300 drives the recruitment of NACK to initiate notch-dependent transcription. Cancer Res 2017;77:4228-4237.
Taniguchi Y. The Bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins. Int J Mol Sci 2016;17:1849.
Dong J, Li J, Li Y, Ma Z, Yu Y, Wang CY. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun 2021;12:3974.
Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA 2019;5:FSO372.
Bohlson SS, Silva R, Fonseca MI, Tenner AJ. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. J Immunol 2005;175:1239-1247.
Zhang M, Bohlson SS, Dy M, Tenner AJ. Modulated interaction of the ERM protein, moesin, with CD93. Immunology 2005;115:63-73.
Kim SM, Park YY, Park ES, et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 2010;5:e15074.
Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 2016;54:1.30.1-1.30.33.
Taylor C, Loomans HA, Le Bras GF, et al. Activin A signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. Oncotarget 2015;6:34228-34244. https://doi.org/10.18632/oncotarget.5349.
Blum AE, Venkitachalam S, Ravillah D, et al. Systems biology analyses show Hyperactivation of transforming growth factor-β and JNK signaling pathways in esophageal cancer. Gastroenterology. 2019;156(6):1761-1774.
Seder CW, Hartojo W, Lin L, et al. INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. J Thorac Oncol 2009;4:455-462.
Altevogt P, Doberstein K, Fogel M. L1CAM in human cancer. Int J Cancer 2016;138:1565-1576.
Guo JC, Xie YM, Ran LQ, et al. L1CAM drives oncogenicity in esophageal squamous cell carcinoma by stimulation of ezrin transcription. J Mol Med (Berl) 2017;95:1355-1368.
He F, Ai B, Tian L. Identification of genes and pathways in esophageal adenocarcinoma using bioinformatics analysis. Biomed Rep 2018;9:305-312.
Placencio VR, DeClerck YA. Plasminogen activator Inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Res 2015;75:2969-2974.
Borg D, Hedner C, Nodin B, et al. Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clin Pathol 2016;16:13.
Zhu L, Yang F, Wang L, et al. Identification the ferroptosis-related gene signature in patients with esophageal adenocarcinoma. Cancer Cell Int 2021;21:124.
Assinder SJ, Stanton JA, Prasad PD. Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009;41:482-486.
Yazdian-Robati R, Ahmadi H, Riahi MM, et al. Comparative proteome analysis of human esophageal cancer and adjacent normal tissues. Iran J Basic Med Sci 2017;20:265-271.
Qi Y, Chiu JF, Wang L, Kwong DL, He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 2005;5:2960-2971.
Pawar H, Kashyap MK, Sahasrabuddhe NA, et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther 2011;12:510-522.
Dvorakova M, Nenutil R, Bouchal P. Transgelins, cytoskeletal proteins implicated in different aspects of cancer development. Expert Rev Proteomics 2014;11:149-165.
Long Y, Tsai WB, Chang JT, et al. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Oncotarget 2016;7:82658-82670. https://doi.org/10.18632/oncotarget.12308.
Lagarde SM, Loren V, van Themaat PE, Moerland PD, et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol 2008;15:3459-3470.
Shiraishi H, Mikami T, Aida J, et al. Telomere shortening in Barrett's mucosa and esophageal adenocarcinoma and its association with loss of heterozygosity. Scand J Gastroenterol 2009;44:538-544.
Okawa T, Michaylira CZ, Kalabis J, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev 2007;21:2788-2803.
Korbut E, Janmaat VT, Wierdak M, et al. Molecular profile of Barrett's esophagus and gastroesophageal reflux disease in the development of translational physiological and pharmacological studies. Int J Mol Sci 2020;21:6436.
Vercauteren Drubbel A, Pirard S, Kin S, et al. Reactivation of the hedgehog pathway in esophageal progenitors turns on an embryonic-like program to initiate columnar metaplasia. Cell Stem Cell 2021;28:1411-1427.e7.
Du ZP, Wu BL, Wu X, et al. A systematic analysis of human lipocalin family and its expression in esophageal carcinoma. Sci Rep 2015;5:12010.
Wu B, Li C, Du Z, et al. Network based analyses of gene expression profile of LCN2 overexpression in esophageal squamous cell carcinoma. Sci Rep 2014;4:5403.
Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest 2017;127:780-789.
Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Biol 2014;772:229-262.
He C, Li Y, Zhang R, Chen J, Feng X, Duan Y. Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma. Oncol Lett 2021;21:478.
Ning G, Huang YL, Zhen LM, et al. Prognostic value of complement component 2 and its correlation with immune infiltrates in hepatocellular carcinoma. Biomed Res Int 2020;2020:3765937.
Breindel JL, Skibinski A, Sedic M, et al. Epigenetic reprogramming of lineage-committed human mammary epithelial cells requires DNMT3A and loss of DOT1L. Stem Cell Rep 2017;9:943-955.
Götzel K, Chemnitzer O, Maurer L, et al. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence. BMC Gastroenterol 2019;19:38.
Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int 2019;19:106.
Yang CM, Wang TH, Chen HC, et al. Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer. Clin Epigenetics 2016;8:129.
Wei AW, Li LF. Long non-coding RNA SOX21-AS1 sponges miR-145 to promote the tumorigenesis of colorectal cancer by targeting MYO6. Biomed Pharmacother 2017;96:953-959.
Jin M, Li D. A Novel Ferroptosis-Related Lncrnas Signature for Prognosis Prediction in Patients with Papillary Renal Cell Carcinoma, 23 June 2021, PREPRINT (Version 1) available at Research Square. https://doi.org/10.21203/rs.3.rs-625377/v1
Kamogashira T, Hayashi K, Fujimoto C, et al. Functionally and morphologically damaged mitochondria observed in auditory cells under senescence-inducing stress. npj Aging Mech Dis 2017;3:2.
Abdel Mouti M, Pauklin S. TGFB1/INHBA homodimer/nodal-SMAD2/3 signaling network: a pivotal molecular target in PDAC treatment. Mol Ther 2021;29:920-936.
Song S, Qiu D, Luo F, et al. Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells. J Mol Endocrinol 2018;61:101-113.
Goossens V, De Vos K, Vercammen D, et al. Redox regulation of TNF signaling. Biofactors 1999;10:145-156.
Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, et al. Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 2010;10:537-542.
Yamakawa N, Tsuchida K, Sugino H. The rasGAP-binding protein, Dok-1, mediates activin signaling via serine/threonine kinase receptors. EMBO J 2002;21:1684-1694.
Gao M, Yi J, Zhu J, et al. Role of mitochondria in ferroptosis. Mol Cell 2019;73:354-363.e3.